New, well-characterized AAV reference standards enable accurate measurement of full and empty capsids, improving assay ...
Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.
The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.
An AAV vector genome integration event associated with PLAG1 overexpression was identified in a preliminary analysis of the resected tumor.
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
Siren plans to initiate a first-in-human clinical study in adult patients with recurrent high-grade glioma. This advancement ...
(Yicai) Jan. 28 -- Chinese medical researchers have made a breakthrough in gene therapy that overcomes the limitations of ...
Opus Genetics is conducting a trial for OPGx-MERTK gene therapy in Abu Dhabi, targeting MERTK-related retinitis pigmentosa using AAV-based delivery. The trial is a collaboration with Cleveland Clinic ...
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic ...
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results